Arrowhead Pharma (ARWR) Stock Price, Quote & News

Company Profile

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitryp...

Industry: Biotechnology

Sector: Healthcare

Phone: 626 304 3400

Fax: 626 304 3401

Website: arrowheadpharma.com

Address:

177 East Colorado Boulevard, Suite 700, Pasadena, United States

skeezbag Aug. 6 at 7:02 PM

$ARWR sub 16 coming the make chart look like shit wins again

0 · Reply

Jschwarma Aug. 6 at 6:05 PM

$ARWR 90th straight day green for $ALNY $ARWR lives under the porch and is creepy uncles favorite

1 · Reply

skeezbag Aug. 6 at 4:32 PM

$ARWR unfortunately great analysis like this doesn't matter when the make the chart look like shit algo is running the company

0 · Reply

Jschwarma Aug. 6 at 4:21 PM

$ARWR fking hold on to momentum jesus christ

0 · Reply

sque Aug. 6 at 4:13 PM

$ARWR Hopefully big whale can buy more At Later part of supporting

0 · Reply

TheSteveSmiths1 Aug. 6 at 3:53 PM

$ARWR some volume pickup. thats nice to see.

0 · Reply

Jschwarma Aug. 6 at 3:35 PM

$ARWR this needs to be considered for BO!!!

1 · Reply

Lolobel Aug. 6 at 3:35 PM

$ARWR 🧨

0 · Reply

skeezbag Aug. 6 at 3:33 PM

$ARWR still means arwr is worth less than 17

0 · Reply

johnnygogogo Aug. 6 at 3:25 PM

$ARWR RNA buyout being considered by NVS being reported

1 · Reply

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

Jul 28, 2025, 7:30 AM EDT - 9 days ago

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

SRPT

Jul 24, 2025, 4:30 PM EDT - 13 days ago

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Jul 23, 2025, 8:00 AM EDT - 14 days ago

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

Jul 22, 2025, 1:30 PM EDT - 15 days ago

How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals

SRPT

Jul 21, 2025, 4:01 PM EDT - 16 days ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

Jul 8, 2025, 7:30 AM EDT - 4 weeks ago

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Jun 23, 2025, 7:30 AM EDT - 6 weeks ago

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

Jun 4, 2025, 8:02 AM EDT - 2 months ago

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'

Jun 2, 2025, 7:30 AM EDT - 2 months ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

May 29, 2025, 7:30 AM EDT - 2 months ago

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences

May 12, 2025, 9:56 PM EDT - 3 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 3 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

May 7, 2025, 7:30 AM EDT - 3 months ago

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

Apr 30, 2025, 4:01 PM EDT - 3 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

Apr 15, 2025, 4:00 PM EDT - 4 months ago

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

Mar 21, 2025, 5:56 PM EDT - 4 months ago

Arrowhead Pharmaceuticals Is Finally Arriving

Mar 10, 2025, 7:30 AM EDT - 5 months ago

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

Mar 6, 2025, 8:45 AM EST - 5 months ago

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

Feb 28, 2025, 9:00 AM EST - 5 months ago

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

Feb 25, 2025, 7:30 AM EST - 5 months ago

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity

Feb 19, 2025, 11:53 AM EST - 6 months ago

Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions

Feb 19, 2025, 10:41 AM EST - 6 months ago

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

AZN BHVN KROS LLY NVO REGN SRRK

Feb 18, 2025, 10:20 AM EST - 6 months ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

AUB CRK CYTK EXE KRYS MARA MP

Feb 10, 2025, 9:35 PM EST - 6 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript

Feb 10, 2025, 4:01 PM EST - 6 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

Feb 10, 2025, 8:30 AM EST - 6 months ago

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

SRPT

Jan 22, 2025, 5:54 PM EST - 6 months ago

Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

B GWRE

Jan 22, 2025, 4:00 PM EST - 6 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

Jan 17, 2025, 4:30 PM EST - 7 months ago

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Dec 23, 2024, 7:30 AM EST - 8 months ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Dec 11, 2024, 7:30 AM EST - 8 months ago

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

Dec 3, 2024, 7:30 AM EST - 8 months ago

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Dec 2, 2024, 7:30 AM EST - 8 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences

Nov 26, 2024, 11:08 PM EST - 9 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2024 Earnings Call Transcript

Nov 26, 2024, 4:00 PM EST - 9 months ago

Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results

Nov 26, 2024, 7:00 AM EST - 9 months ago

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs

SRPT

Nov 18, 2024, 7:31 AM EST - 9 months ago

Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Nov 18, 2024, 7:30 AM EST - 9 months ago

Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran

Nov 5, 2024, 7:30 AM EST - 9 months ago

Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results

Nov 4, 2024, 7:30 AM EST - 9 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences

Nov 1, 2024, 7:30 AM EDT - 9 months ago

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We'll Get There Soon,' to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome

Sep 23, 2024, 7:30 AM EDT - 11 months ago

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Sep 10, 2024, 7:30 AM EDT - 11 months ago

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran

Sep 3, 2024, 11:01 AM EDT - 1 year ago

Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug

Sep 2, 2024, 6:36 AM EDT - 1 year ago

Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Aug 21, 2024, 7:30 AM EDT - 1 year ago

Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Aug 14, 2024, 6:59 PM EDT - 1 year ago

Arrowhead Pharmaceuticals, Inc. (ARWR) 2024 Summer Series R&D Webinar: Obesity/Metabolic - ARO-INHBE Conference (Transcript)

Aug 14, 2024, 1:30 PM EDT - 1 year ago

Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results

skeezbag Aug. 6 at 7:02 PM

$ARWR sub 16 coming the make chart look like shit wins again

0 · Reply

Jschwarma Aug. 6 at 6:05 PM

$ARWR 90th straight day green for $ALNY $ARWR lives under the porch and is creepy uncles favorite

1 · Reply

skeezbag Aug. 6 at 4:32 PM

$ARWR unfortunately great analysis like this doesn't matter when the make the chart look like shit algo is running the company

0 · Reply

Jschwarma Aug. 6 at 4:21 PM

$ARWR fking hold on to momentum jesus christ

0 · Reply

sque Aug. 6 at 4:13 PM

$ARWR Hopefully big whale can buy more At Later part of supporting

0 · Reply

TheSteveSmiths1 Aug. 6 at 3:53 PM

$ARWR some volume pickup. thats nice to see.

0 · Reply

Jschwarma Aug. 6 at 3:35 PM

$ARWR this needs to be considered for BO!!!

1 · Reply

Lolobel Aug. 6 at 3:35 PM

$ARWR 🧨

0 · Reply

skeezbag Aug. 6 at 3:33 PM

$ARWR still means arwr is worth less than 17

0 · Reply

johnnygogogo Aug. 6 at 3:25 PM

$ARWR RNA buyout being considered by NVS being reported

1 · Reply

fredster45 Aug. 6 at 3:00 PM

$ARWR from coldlander: https://www.clinicaltrials.gov/study/NCT05537025?term=%22arrowhead%20pharmaceuticals%22&aggFilters=status:not%20rec%20act&rank=13&tab=history&a=21&b=22#version-content-panel

0 · Reply

sque Aug. 6 at 2:57 PM

$ARWR Wait for Vanguard Blue whale buying deep First We stay and standby

1 · Reply

skeezbag Aug. 6 at 2:41 PM

$ARWR sector can rally now and price can stay below $16. Options and shorts do more than insiders today determine valuation

0 · Reply

johnnygogogo Aug. 6 at 2:19 PM

$ARWR literally everyone knows this is mispriced. Whatever market makers. Keep making lies. (Yes I see the whole sector is down, I don’t care).

0 · Reply

Jschwarma Aug. 6 at 1:49 PM

$ARWR trading like absolute horse shit. No volume, downside pressure. Visirna deal means zero. christ sakes

0 · Reply

johnnygogogo Aug. 6 at 1:21 PM

$ARWR Olpasiran (ie. Ol’ ARO-AAT) on track over at $AMGN fwiw. Second CVOT starting in 2H25 / 1H26.

1 · Reply

CH_Expat Aug. 5 at 6:42 PM

$ARWR What is the goddamn EV of this Phase-2-Powerhouse? 800m? A joke.

1 · Reply

sque Aug. 5 at 4:25 PM

$ARWR Add more below 👇$16 50 Vanguard is big whale 🐳

1 · Reply

johnnygogogo Aug. 5 at 4:06 PM

$ARWR @skeezbag I’m bored, let’s play guess the close. Price is right rules, closest without going over. I’m guessing 16.79 because I saw it in the premarket and it’s still right below the 20-day SMA fakeness. You?

2 · Reply

skeezbag Aug. 5 at 3:42 PM

$ARWR stock is definitely not worth more than 17

2 · Reply

sque Aug. 5 at 2:14 PM

$ARWR Big whale 🐳🐳🐳 😊 Hello 👋

0 · Reply

sque Aug. 5 at 2:10 PM

$ARWR add more below 👇 $16.50

0 · Reply

Market Cap	2.27B
Revenue (ttm)	3.55M
Net Income (ttm)	-599.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	162.25
Profit Margin	-16,887.04%
Debt to Equity Ratio	0.40

Volume	1,902,398
Avg Vol	1,772,684
Day's Range	N/A - N/A
Shares Out	138.10M
Stochastic %K	82%
Beta	0.94
Analysts	Strong Sell
Price Target	$44.00